A detailed history of American Century Companies Inc transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, American Century Companies Inc holds 586,322 shares of VRTX stock, worth $295 Million. This represents 0.17% of its overall portfolio holdings.

Number of Shares
586,322
Previous 694,894 15.62%
Holding current value
$295 Million
Previous $290 Million 5.39%
% of portfolio
0.17%
Previous 0.19%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 07, 2024

SELL
$392.81 - $485.53 $42.6 Million - $52.7 Million
-108,572 Reduced 15.62%
586,322 $275 Million
Q1 2024

May 14, 2024

SELL
$407.69 - $446.08 $43.1 Million - $47.1 Million
-105,643 Reduced 13.2%
694,894 $290 Million
Q4 2023

Feb 13, 2024

BUY
$343.0 - $410.68 $275 Million - $329 Million
800,537 New
800,537 $326 Million
Q3 2023

Nov 13, 2023

SELL
$338.18 - $362.46 $19.1 Million - $20.5 Million
-56,562 Reduced 5.65%
944,868 $329 Million
Q2 2023

Aug 14, 2023

SELL
$314.42 - $351.91 $47 Million - $52.6 Million
-149,472 Reduced 12.99%
1,001,430 $352 Million
Q1 2023

May 11, 2023

BUY
$283.23 - $323.1 $5.63 Million - $6.43 Million
19,887 Added 1.76%
1,150,902 $363 Million
Q4 2022

Feb 13, 2023

SELL
$285.76 - $321.48 $36.9 Million - $41.5 Million
-129,082 Reduced 10.24%
1,131,015 $327 Million
Q3 2022

Nov 14, 2022

BUY
$273.83 - $305.53 $22.1 Million - $24.6 Million
80,563 Added 6.83%
1,260,097 $365 Million
Q2 2022

Aug 12, 2022

BUY
$234.96 - $292.55 $18.5 Million - $23 Million
78,659 Added 7.15%
1,179,534 $332 Million
Q1 2022

May 11, 2022

BUY
$221.42 - $260.97 $105 Million - $124 Million
476,422 Added 76.29%
1,100,875 $287 Million
Q4 2021

Feb 07, 2022

SELL
$177.01 - $223.45 $25.7 Million - $32.4 Million
-145,053 Reduced 18.85%
624,453 $137 Million
Q3 2021

Nov 10, 2021

SELL
$181.39 - $202.99 $23.7 Million - $26.5 Million
-130,754 Reduced 14.52%
769,506 $140 Million
Q2 2021

Aug 05, 2021

BUY
$187.49 - $221.1 $34.3 Million - $40.5 Million
183,075 Added 25.53%
900,260 $182 Million
Q1 2021

May 14, 2021

SELL
$207.02 - $241.31 $44.4 Million - $51.8 Million
-214,647 Reduced 23.03%
717,185 $154 Million
Q4 2020

Feb 12, 2021

SELL
$207.01 - $276.09 $19.9 Million - $26.6 Million
-96,336 Reduced 9.37%
931,832 $220 Million
Q3 2020

Nov 13, 2020

BUY
$255.65 - $303.1 $54.9 Million - $65.1 Million
214,855 Added 26.42%
1,028,168 $280 Million
Q2 2020

Aug 13, 2020

SELL
$225.48 - $295.8 $64.5 Million - $84.6 Million
-285,928 Reduced 26.01%
813,313 $236 Million
Q1 2020

May 14, 2020

SELL
$199.77 - $247.81 $5.32 Million - $6.6 Million
-26,623 Reduced 2.36%
1,099,241 $262 Million
Q4 2019

Feb 12, 2020

BUY
$166.71 - $223.91 $22.7 Million - $30.4 Million
135,987 Added 13.74%
1,125,864 $247 Million
Q3 2019

Nov 13, 2019

BUY
$166.23 - $187.09 $11.4 Million - $12.9 Million
68,701 Added 7.46%
989,877 $168 Million
Q2 2019

Aug 14, 2019

BUY
$164.61 - $190.37 $1.82 Million - $2.11 Million
11,067 Added 1.22%
921,176 $169 Million
Q1 2019

May 14, 2019

SELL
$163.73 - $194.7 $8.1 Million - $9.63 Million
-49,448 Reduced 5.15%
910,109 $0
Q4 2018

Feb 13, 2019

SELL
$151.91 - $192.21 $28.7 Million - $36.3 Million
-188,868 Reduced 16.45%
959,557 $159 Million
Q3 2018

Nov 02, 2018

BUY
$167.73 - $192.74 $3.86 Million - $4.43 Million
22,997 Added 2.04%
1,148,425 $221 Million
Q2 2018

Aug 08, 2018

BUY
$145.72 - $169.96 $128 Million - $149 Million
879,411 Added 357.46%
1,125,428 $191 Million
Q1 2018

May 03, 2018

BUY
$151.6 - $177.13 $10.3 Million - $12 Million
67,911 Added 38.13%
246,017 $40.1 Million
Q4 2017

Feb 02, 2018

BUY
$137.28 - $155.55 $2 Million - $2.26 Million
14,560 Added 8.9%
178,106 $26.7 Million
Q3 2017

Nov 01, 2017

BUY
$148.13 - $162.24 $24.2 Million - $26.5 Million
163,546
163,546 $24.9 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $129B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track American Century Companies Inc Portfolio

Follow American Century Companies Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of American Century Companies Inc, based on Form 13F filings with the SEC.

News

Stay updated on American Century Companies Inc with notifications on news.